Methods and Compositions for Treating Osteoarthritis
AssigneeGenascence Corporation
InventorsThomas W. Chalberg, Jr., Annahita Keravala
Life of this patent
Estimating the term…
Abstract
Methods for treating a human suffering from osteoarthritis are provided. Aspects of the methods include intra-articularly administering to the human a dosage comprising a nucleic acid coding sequence for a human interleukin-1 receptor antagonist (IL-1Ra) in combination with a dosage of an immunomodulatory agent to treat the human suffering from osteoarthritis. Also provided are compositions for use in practicing the methods.
Claims15
A method for treating a human suffering from osteoarthritis, the method comprising:
- co-administering to the human:
- a dosage comprising a nucleic acid coding sequence for a human interleukin-1 receptor antagonist (IL-1Ra);
- and
- a dosage comprising an immunomodulatory agent;
- to treat the human suffering from osteoarthritis;
- wherein the dosage comprising the nucleic acid coding sequence for a human interleukin-1 receptor antagonist (IL-1Ra) is intra-articularly administered.
The method according to any of the preceding claims, wherein the coding sequence comprises a sequence that is 80% or more identical to SEQ ID NOS:
- 4 or 5.
The method according to any of the preceding claims, wherein the coding sequence is operatively linked to a promoter, preferably a non-human promoter, preferably a viral promoter, preferably a cytomegalovirus immediate early promoter.
The method according to any of the preceding claims, wherein the dosage has a volume ranging from 0.25 to 25 ml.
The method according to any of the preceding claims, wherein the method comprises intra-articularly administering only a single dosage of the nucleic acid coding sequence for a human interleukin-1 receptor antagonist (IL-1Ra).
The method according to any of the preceding claims, wherein the immunomodulatory agent is selected from a steroid, a complement inhibitor, a CD20 binding agent, a macrolide calcineurin inhibitor, a T-lymphocyte activation and proliferation inhibitor, and a B-lymphocyte activation and proliferation inhibitor.
The method according to any of the preceding claims, wherein the dosage of immunomodulatory agent is administered systemically and/or locally.
The method according to any of the preceding claims, wherein the method further comprises administering one or more additional dosages of the immunomodulatory agent after administration of the dosage of the nucleic acid coding sequence for a human interleukin-1 receptor antagonist (IL-1Ra).
The method according to any of the preceding claims, wherein the osteoarthritis is selected from the group consisting osteoarthritis of the hand, knee, hip, shoulder, ankle, foot, elbow, temporomandibular joint, and spine, and combinations thereof, wherein the osteoarthritis is preferably osteoarthritis of the knee.
Dependencies are inferred from the claim text.